SCHEMBL3016975

SCHEMBL3016975

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.54
RAB9A P51151 5/20 0.54
MAPT P10636 7/20 0.52
NPC1 O15118 3/20 0.51
USP2 O75604 3/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALDH1A1 P00352 6/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 5/20 0.46
LMNA P02545 4/20 0.46
KCNQ1 P51787 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM1A O60341 1/20 0.44
MAOA P21397 1/20 0.44
MMP1 P03956 1/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44
MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008539 0.95 MAPT (0.52) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3018971 0.93 MAPT (0.52) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3013823 0.92 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3021368 0.91 SMN1; SMN2 (0.46) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3007143 0.91 MAPT (0.63) SMN1; SMN2RAB9AMAPTUSP2RECQL
SCHEMBL3017092 0.90 SMN1; SMN2 (0.52) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3011801 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3001728 0.90 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3017259 0.89 MAPT (0.52) SMN1; SMN2RAB9AMAPTNPC1USP2
SCHEMBL3016686 0.89 RAB9A (0.59) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.